All In Biotech

Drug Trial Radar · NCT05161195

Roll-over Study to Allow Continued Access to Ribociclib

A Post-trial Access Roll-over Study to Allow Access to Ribociclib (LEE011) for Patients Who Are on Ribociclib Treatment in Novartis-sponsored Study

Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

134

Actual

Start

Jul 7, 2022

Primary completion

Jun 28, 2030

Study completion Aug 14, 2030

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Dec 17, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the long-term safety of ribociclib (LEE011) in combination with other drugs and provide post-trial access (PTA) to participants who are currently receiving treatment with ribociclib in combination with other drugs and continuing to have clinical benefit in a Novartis-sponsored global study that has reached its primary objective(s).

Conditions

  • Metastatic Breast Cancer

Interventions

  • RibociclibDrug

    Participants continue ribociclib as was administered in their parent study

  • LetrozoleDrug

    Participants continue ribociclib in combination with letrozole as was administered in their parent study

  • AnastrozoleDrug

    Participants continue ribociclib in combination with anastrozole as was administered in their parent study

  • GoserelinDrug

    Participants continue ribociclib in combination with goserelin as was administered in their parent study

  • TamoxifenDrug

    Participants continue ribociclib in combination with tamoxifen as was administered in their parent study

  • FulvestrantDrug

    All participants continue ribociclib in combination with fulvestrant as was administered in their parent study

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with treatment-emergent adverse events (AES)Time frame: From day of first dose of study medication to 30 days after last dose of study medication, up to 8 years

Locations

73 sites in 22 countries. Site status is shown where the registry gives one.

  • Ironwood Cancer and Research Centers

    Chandler, Arizona

  • Highlands Oncology Group

    Fayetteville, Arkansas

  • Beverly Hills Cancer Center

    Beverly Hills, California

  • Poudre Valley Hospital

    Fort Collins, Colorado

  • Mid Florida Hematology And Onc Ctr

    Orange, Florida

  • Summit Cancer Care

    Savannah, Georgia

  • John D Archbold Memorial Hospital

    Thomasville, Georgia

  • Duly Health and Care

    Plainfield, Illinois

  • Indian Univ Health Goshen Center forCancer

    Goshen, Indiana

  • Northern Light Mercy Hospital

    Portland, Maine

  • Englewood Health

    Englewood, New Jersey

  • The Valley Hospital-Luckow Pavillion

    Paramus, New Jersey

  • Eastchester Center for Cancer Care

    The Bronx, New York

  • University Hospitals of Cleveland Seidman Cancer Center

    Cleveland, Ohio

  • Oklahoma Cancer Specialists and Research Institute

    Tulsa, Oklahoma

  • Millennium Research Clin Develop

    Houston, Texas

  • Novartis Investigative Site

    San Juan, Argentina

  • Novartis Investigative Site

    São Paulo, Brazil

  • Novartis Investigative Site

    Natal, Rio Grande do Norte, Brazil

  • Novartis Investigative Site

    Ijuí, Rio Grande do Sul, Brazil

  • Novartis Investigative Site

    Florianópolis, Santa Catarina, Brazil

  • Novartis Investigative Site

    São José do Rio Preto, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Qingdao, China

  • Novartis Investigative Site

    Shanghai, China

  • Novartis Investigative Site

    Shanghai, China

  • Novartis Investigative Site

    Tianjin, China

  • Novartis Investigative Site

    Chongqing, Chongqing Municipality, China

  • Novartis Investigative Site

    Shijiazhuang, Hebei, China

  • Novartis Investigative Site

    Harbin, Heilongjiang, China

  • Novartis Investigative Site

    Changsha, Hunan, China

  • Novartis Investigative Site

    Nanjing, Jiangsu, China

  • Novartis Investigative Site

    Suzhou, Jiangsu, China

  • Novartis Investigative Site

    Changchun, Jilin, China

  • Novartis Investigative Site

    Kunming, Yunnan, China

  • Novartis Investigative Site

    Hangzhou, Zhejiang, China

  • Novartis Investigative Site

    Hangzhou, Zhejiang, China

  • Novartis Investigative Site

    San José, CR, Costa Rica

Showing 40 of 73 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.